← Back to headlines
Arbutus Biopharma Stock Surges on $230 Million Buyback Plan
Arbutus Biopharma stock surged significantly after the company announced a $230 million buyback plan. This move indicates confidence from the company and has been positively received by investors.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
HDFC Bank CEO Sashidhar Jagdishan to Step Down in October
1h ago
FSSAI Bans Everest and Laljee Godhoo From Selling Substandard Hing Powder
2h ago
UAE Central Bank Launches Probe Into Banque Misr Over US Money Laundering Warnings
3h ago
S&P, Nasdaq end lower after Fed Chair Warsh reaffirms inflation fight - Reuters
3h ago